Therapeutic antibodies for autoimmunity and inflammation

Nat Rev Immunol. 2010 May;10(5):301-16. doi: 10.1038/nri2761.


The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Bispecific / therapeutic use*
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibody-Dependent Cell Cytotoxicity
  • Autoimmune Diseases / drug therapy*
  • Cytokines / antagonists & inhibitors
  • Half-Life
  • Humans
  • Inflammation / drug therapy*
  • Intercellular Signaling Peptides and Proteins / immunology


  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • Cytokines
  • Intercellular Signaling Peptides and Proteins